Drug intelligence / Profile preview

adebrelimab + apatinib + fluzoparib + famitinib

Development stage: Preclinical
Lead developer: Hengrui Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of adebrelimab (an anti-PD-L1 monoclonal antibody), apatinib (a VEGFR2 inhibitor), fluzoparib (a PARP inhibitor), and famitinib. This specific four-drug combination is not documented in the available literature based on the provided search results.

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRB (Platelet-derived growth factor receptor beta)CD274 (Programmed cell death protein 1 ligand 1)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PARP2 (Poly (adp-ribose) polymerase 2)

Beyond the preview

Go deeper on adebrelimab + apatinib + fluzoparib + famitinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adebrelimab + apatinib + fluzoparib + famitinib.

Explore the full profile